Research programme: inhaled dry powder respiratory therapeutic - Novartis/MicroDose Therapeutx

Drug Profile

Research programme: inhaled dry powder respiratory therapeutic - Novartis/MicroDose Therapeutx

Latest Information Update: 13 Jun 2014

Price : $50

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Respiratory tract disorders

Most Recent Events

  • 08 Jul 2013 MicroDose Therapeutx has been acquired by Teva Pharmaceutical Industries
  • 03 May 2011 Preclinical development is ongoing in Switzerland
  • 13 Jul 2010 Preclinical development is ongoing in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top